EFFECT OF EARLY INTENSIVE TREATMENT WITH ROSUVASTATIN ON SERUM HYPERSENSITIVE C-REACTIVE PROTEIN, IL-6 LEVEL AND CARDIAC FUNCTION IN PATIENTS WITH ACUTE CORONARY SYNDROME AFTER PCI

Hongguang Zhu,  Qingyan Wang,  Xin Huang^* 

Department of Cardiology, Yantai Harbour Hospltal, Yantai, 264000,Shandong Province, China

Objective: The purpose was to explore the effect of early intensive treatment with rosuvastatin on serum hypersensitive C-reactive protein, IL-6 level and cardiac function in patients with acute coronary syndrome (ACS) after PCI. 

Methods: 100 ACS patients treated by PCI in our hospital from May 2018 to March 2020 were selected as the study subjects, and divided into routine group (n=50) and intensive group (n=50) according to their order of admission. Both groups of patients underwent PCI in a routine manner and were treated with rosuvastatin 7 days before surgery. The routine group was treated with 10mg/d of rosuvastatin while the intensive group was treated with 20mg/d of rosuvastatin to analyze the serum hypersensitive C-reactive protein, IL-6 level, cardiac function (LVEF, LVSD, LVDD and E/A) and adverse event rate after PCI in two groups of patients. 

Results: After operation, the hs-CRP level of the intensive group was significantly lower than that of the routine group, with statistical significance (T=8.10, P<0.001). The IL-6 level of the intensive group was significantly lower than that of the routine group, with statistical significance (T=7.32, P<0.001). LVEF and E/A levels of the intensive group were significantly higher than those of the routine group while LVSD and LVDD levels of the intensive group were significantly lower than those of the routine group, with statistical significance (T=3.91, 4.01, 3.68, 3.72; P<0.001). The adverse event rate of the intensive group was significantly lower than that of the routine group, with statistical significance (X²=13.56, P<0.001). 

Conclusion: Early intensive treatment with rosuvastatin in ACS patients with PCI can effectively improve inflammatory factors, enhance cardiac function and reduce the occurrence of adverse events, which is worthy of popularization and application in clinical practice.